The proprotein convertase furin in tumour progression

International Journal of Cancer

Volumn 141, Issue 4, 2017, Pages 654-663

  Jaaks, Patricia ^a   Bernasconi, Michele ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

breast cancer; furin; growth factors; lung carcinoma; MT MMP; proprotein convertases; rhabdomyosarcoma; tumor progression

Indexed keywords

CANCER VACCINE; CELL ADHESION MOLECULE; FURIN; FURIN KNOCKDOWN AND GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR AUGMENTED CANCER VACCINE; GADOLINIUM; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IMMUNOTOXIN; IMMUNOTOXIN SS1P; METALLOPROTEINASE; NANOBODY; NANOPARTICLE; PROTEIN PRECURSOR; SERINE PROTEINASE; UNCLASSIFIED DRUG; FURIN PROTEIN, HUMAN;

ADVANCED CANCER; BREAST CANCER; CANCER CELL; CARCINOGENESIS; ENZYME ACTIVITY; ENZYME SUBSTRATE; EWING SARCOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; RHABDOMYOSARCOMA; TUMOR GROWTH; ANIMAL; DISEASE COURSE; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; NEOPLASM; TUMOR INVASION;

ANIMALS; DISEASE PROGRESSION; FURIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 85020943811     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30714     Document Type: Review

References (125)

1. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012;11:367–83.
2. Jackson RS, Creemers JW, Ohagi S, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997;16:303–6.
3. Bennett BD, Denis P, Haniu M, et al. A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's beta -secretase. J Biol Chem 2000;275:37712–7.
4. Khatib AM, Siegfried G, Chretien M, et al. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 2002;160:1921–35.
5. Bassi DE, Fu J, Lopez de Cicco R, et al. Proprotein convertases: “master switches” in the regulation of tumor growth and progression. Mol Carcinog 2005;44:151–61.
6. Seidah NG, Day R, Marcinkiewicz M, et al. Precursor convertases: an evolutionary ancient, cell-specific, combinatorial mechanism yielding diverse bioactive peptides and proteins. Ann N Y Acad Sci 1998;839:9–24.
7. Anderson ED, VanSlyke JK, Thulin CD, et al. Activation of the furin endoprotease is a multiple-step process: requirements for acidification and internal propeptide cleavage. Embo J 1997;16:1508–18.
8. Molloy SS, Bresnahan PA, Leppla SH, et al. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem 1992;267:16396–402.
9. Henrich S, Cameron A, Bourenkov GP, et al. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 2003;10:520–6.
10. Dahms SO, Hardes K, Becker GL, et al. X-ray structures of human furin in complex with competitive inhibitors. ACS Chem Biol 2014;9:1113–8.
11. Hardes K, Becker GL, Lu Y, et al. Novel furin inhibitors with potent anti-infectious activity. ChemMedChem 2015;10:1218–31.
12. Dahms SO, Arciniega M, Steinmetzer T, et al. Structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism. Proc Natl Acad Sci USA 2016;113:11196–201.
13. McMahon S, Grondin F, McDonald PP, et al. Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem 2005;280:6561–9.
14. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008;111:924–31.
15. Krijt J, Fujikura Y, Sefc L, et al. Hepcidin downregulation by repeated bleeding is not mediated by soluble hemojuvelin. Physiol Res 2010;59:53–9.
16. Fu J, Zhang J, Gong Y, et al. Regulation of HIF-1 alpha by the proprotein convertases furin and PC7 in human squamous carcinoma cells. Mol Carcinog 2015;54:698–706.
17. Arsenault D, Lucien F, Dubois CM, Hypoxia enhances cancer cell invasion through relocalization of the proprotein convertase furin from the trans-Golgi network to the cell surface. J Cell Physiol 2012;227:789–800.
18. Blanchette F, Day R, Dong W, et al. TGFbeta1 regulates gene expression of its own converting enzyme furin. J Clin Invest 1997;99:1974–83.
19. Blanchette F, Rudd P, Grondin F, et al. Involvement of smads in TGFbeta1-induced furin (fur) transcription. J Cell Physiol 2001;188:264–73.
20. Chen RN, Huang YH, Lin YC, et al. Thyroid hormone promotes cell invasion through activation of furin expression in human hepatoma cell lines. Endocrinology 2008;149:3817–31.
21. Brant KA, Leikauf GD, Dysregulation of FURIN by prostaglandin-endoperoxide synthase 2 in lung epithelial NCI-H292 cells. Mol Carcinog 2014;53:192–200.
22. Anderson ED, Thomas L, Hayflick JS, et al. Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. J Biol Chem 1993;268:24887–91.
23. Garten W, Stieneke A, Shaw E, et al. Inhibition of proteolytic activation of influenza virus hemagglutinin by specific peptidyl chloroalkyl ketones. Virology 1989;172:25–31.
24. Schalken JA, Roebroek AJ, Oomen PP, et al. fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. J Clin Invest 1987;80:1545–9.
25. Mbikay M, Sirois F, Yao J, et al. Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 1997;75:1509–14.
26. Bassi DE, Zhang J, Renner C, et al. Targeting proprotein convertases in furin-rich lung cancer cells results in decreased in vitro and in vivo growth. Mol Carcinog 2016;50:1182–88. DOI 10.1002/mc.22550.
27. Demidyuk IV, Shubin AV, Gasanov EV, et al. Alterations in gene expression of proprotein convertases in human lung cancer have a limited number of scenarios. PLoS One 2013;8:e55752.
28. Bassi DE, Mahloogi H, Al-Saleem L, et al. Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 2001;31:224–32.
29. Lopez de Cicco R, Bassi DE, Page R, et al. Furin expression in squamous cell carcinomas of the oral cavity and other sites evaluated by tissue microarray technology. Acta Odontol Latinoam 2002;15:29–37.
30. Ma YC, Fan WJ, Rao SM, et al. Effect of Furin inhibitor on lung adenocarcinoma cell growth and metastasis. Cancer Cell Int 2014;14:43.
31. Bassi DE, Lopez De Cicco R, Mahloogi H, et al. Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci USA 2001;98:10326–31.
32. Bassi DE, Mahloogi H, Lopez De Cicco R, et al. Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 2003;162:439–47.
33. Lopez de Cicco R, Bassi DE, Zucker S, et al. Human carcinoma cell growth and invasiveness is impaired by the propeptide of the ubiquitous proprotein convertase furin. Cancer Res 2005;65:4162–71.
34. Lopez de Cicco R, Watson JC, Bassi DE, et al. Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression. Clin Cancer Res 2004;10:4480–8.
35. Aznavoorian S, Moore BA, Alexander-Lister LD, et al. Membrane type I-matrix metalloproteinase-mediated degradation of type I collagen by oral squamous cell carcinoma cells. Cancer Res 2001;61:6264–75.
36. Lee M, Ryu CH, Chang HW, et al. Radiotherapy-associated furin expression and tumor invasiveness in recurrent laryngeal cancer. Anticancer Res 2016;36:5117–25.
37. Cheng M, Watson PH, Paterson JA, et al. Pro-protein convertase gene expression in human breast cancer. Int J Cancer 1997;71:966–71.
38. Cheng M, Xu N, Iwasiow B, et al. Elevated expression of proprotein convertases alters breast cancer cell growth in response to estrogen and tamoxifen. J Mol Endocrinol 2001;26:95–105.
39. Lapierre M, Siegfried G, Scamuffa N, et al. Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells' malignant phenotypes: role of tissue inhibitors of metalloproteinase-1. Cancer Res 2007;67:9030–4.
40. Cepeda MA, Evered CL, Pelling JJ, et al. Inhibition of MT1-MMP proteolytic function and ERK1/2 signalling influences cell migration and invasion through changes in MMP-2 and MMP-9 levels. J Cell Commun Signal, in press. doi:10.1007/s12079-016-0373-3.
41. Scamuffa N, Sfaxi F, Ma J, et al. Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis. Carcinogenesis 2014;35:528–36.
42. Singh H, Heng S, Nicholls PK, et al. Proprotein convertases in post-menopausal endometrial cancer: distinctive regulation and non-invasive diagnosis. Biochem Biophys Res Commun 2012;419:809–14.
43. Heng S, Stephens AN, Jobling TW, et al. Total PC activity is increased in uterine lavage of post-menopausal endometrial but not ovarian cancer patients. J Cancer 2016;7:1812–4.
44. Heng S, Stephens AN, Jobling TW, et al. Measuring PC activity in endocervical swab may provide a simple and non-invasive method to detect endometrial cancer in post-menopausal women. Oncotarget 2016;7:46573–8.
45. Kumar V, Behera R, Lohite K, et al. p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Res 2010;70:10381–91.
46. Page RE, Klein-Szanto AJ, Litwin S, et al. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol 2007;29:289–99.
47. Longuespee R, Couture F, Levesque C, et al. Implications of proprotein convertases in ovarian cancer cell proliferation and tumor progression: insights for PACE4 as a therapeutic target. Transl Oncol 2014;7:410–9.
48. Fu Y, Campbell EJ, Shepherd TG, et al. Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol Cancer Res 2003;1:569–76.
49. Nakajima T, Konda Y, Kanai M, et al. Prohormone convertase furin has a role in gastric cancer cell proliferation with parathyroid hormone-related peptide in a reciprocal manner. Dig Dis Sci 2002;47:2729–37.
50. Khatib AM, Siegfried G, Prat A, et al. Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem 2001;276:30686–93.
51. Scamuffa N, Siegfried G, Bontemps Y, et al. Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest 2008;118:352–63.
52. Jaaks P, D'Alessandro V, Grob N, et al. The proprotein convertase Furin contributes to rhabdomyosarcoma malignancy by promoting vascularization, migration and invasion. PLoS One 2016;11:e0161396.
53. Jaaks P, Meier G, Alijaj N, et al. The proprotein convertase Furin is required to maintain viability of alveolar rhabdomyosarcoma cells. Oncotarget 2016;7:76743–55.
54. Maquoi E, Noel A, Frankenne F, et al. Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett 1998;424:262–6.
55. Liu B, Li G, Wang X, et al. A furin inhibitor downregulates osteosarcoma cell migration by downregulating the expression levels of MT1-MMP via the Wnt signaling pathway. Oncol Lett 2014;7:1033–8.
56. Mercapide J, Lopez D, Cicco R, Bassi DE, et al. Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res 2002;8:1740–6.
57. Wick W, Wild-Bode C, Frank B, et al. BCL-2-induced glioma cell invasiveness depends on furin-like proteases. J Neurochem 2004;91:1275–83.
58. Fu J, Bassi DE, Zhang J, et al. Transgenic overexpression of the proprotein convertase furin enhances skin tumor growth. Neoplasia 2012;14:271–82.
59. Fu J, Bassi DE, Zhang J, et al. Enhanced UV-induced skin carcinogenesis in transgenic mice overexpressing proprotein convertases. Neoplasia 2013;15:169–79.
60. Bolt G, Pedersen IR, The role of subtilisin-like proprotein convertases for cleavage of the measles virus fusion glycoprotein in different cell types. Virology 1998;252:387–98.
61. Klimpel KR, Molloy SS, Thomas G, et al. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci USA 1992;89:10277–81.
62. Rawlings ND, Barrett AJ, Finn RD. Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 2016;44:D343–D50.
63. Duguay SJ, Milewski WM, Young BD, et al. Processing of wild-type and mutant proinsulin-like growth factor-IA by subtilisin-related proprotein convertases. J Biol Chem 1997;272:6663–70.
64. Bresnahan PA, Leduc R, Thomas L, et al. Human fur gene encodes a yeast KEX2-like endoprotease that cleaves pro-beta-NGF in vivo. J Cell Biol 1990;111:2851–9.
65. Seidah NG, Benjannet S, Pareek S, et al. Cellular processing of the nerve growth factor precursor by the mammalian pro-protein convertases. Biochem J 1996;314:951–60.
66. Siegfried G, Khatib AM, Benjannet S, et al. The proteolytic processing of pro-platelet-derived growth factor-A at RRKR(86) by members of the proprotein convertase family is functionally correlated to platelet-derived growth factor-A-induced functions and tumorigenicity. Cancer Res 2003;63:1458–63.
67. Siegfried G, Basak A, Prichett-Pejic W, et al. Regulation of the stepwise proteolytic cleavage and secretion of PDGF-B by the proprotein convertases. Oncogene 2005;24:6925–35.
68. Denault JB, Claing A, D'Orleans-Juste P, et al. Processing of proendothelin-1 by human furin convertase. FEBS Lett 1995;362:276–80.
69. Hendy GN, Bennett HP, Gibbs BF, et al. Proparathyroid hormone is preferentially cleaved to parathyroid hormone by the prohormone convertase furin. A mass spectrometric study. J Biol Chem 1995;270:9517–25.
70. Dubois CM, Laprise MH, Blanchette F, et al. Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 1995;270:10618–24.
71. Leitlein J, Aulwurm S, Waltereit R, et al. Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. J Immunol 2001;166:7238–43.
72. Yana I, Weiss SJ, Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 2000;11:2387–401.
73. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61–5.
74. Ohuchi E, Imai K, Fujii Y, et al. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997;272:2446–51.
75. Lee AY, Akers KT, Collier M, et al. Intracellular activation of gelatinase A (72-kDa type IV collagenase) by normal fibroblasts. Proc Natl Acad Sci USA 1997;94:4424–9.
76. Cao J, Rehemtulla A, Pavlaki M, et al. Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase. J Biol Chem 2005;280:10974–80.
77. Kang T, Nagase H, Pei D, Activation of membrane-type matrix metalloproteinase 3 zymogen by the proprotein convertase furin in the trans-Golgi network. Cancer Res 2002;62:675–81.
78. Wang X, Pei D. Shedding of membrane type matrix metalloproteinase 5 by a furin-type convertase: a potential mechanism for down-regulation. J Biol Chem 2001;276:35953–60.
79. Pei D, Weiss SJ, Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995;375:244–7.
80. Santavicca M, Noel A, Angliker H, et al. Characterization of structural determinants and molecular mechanisms involved in pro-stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases. Biochem J 1996;315:953–8.
81. Kuno K, Terashima Y, Matsushima K, ADAMTS-1 is an active metalloproteinase associated with the extracellular matrix. J Biol Chem 1999;274:18821–6.
82. Loechel F, Gilpin BJ, Engvall E, et al. Human ADAM 12 (meltrin alpha) is an active metalloprotease. J Biol Chem 1998;273:16993–7.
83. Schlöndorff J, Becherer JD, Blobel CP. Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). Biochem J 2000;347:131–8.
84. Sharma A, Bender S, Zimmermann M, et al. Secretome signature identifies ADAM17 as novel target for radiosensitization of non-small cell lung cancer. Clin Cancer Res 2016;22:4428–39.
85. Lehmann M, Rigot V, Seidah NG, et al. Lack of integrin alpha-chain endoproteolytic cleavage in furin-deficient human colon adenocarcinoma cells LoVo. Biochem J 1996;317:803–9.
86. Lissitzky JC, Luis J, Munzer JS, et al. Endoproteolytic processing of integrin pro-alpha subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PC5B or PC7. Biochem J 2000;346:133–8.
87. Bergeron E, Basak A, Decroly E, et al. Processing of alpha4 integrin by the proprotein convertases: histidine at position P6 regulates cleavage. Biochem J 2003;373:475–84.
88. Posthaus H, Dubois CM, Laprise MH, et al. Proprotein cleavage of E-cadherin by furin in baculovirus over-expression system: potential role of other convertases in mammalian cells. FEBS Lett 1998;438:306–10.
89. Maret D, Gruzglin E, Sadr MS, et al. Surface expression of precursor N-cadherin promotes tumor cell invasion. Neoplasia 2010;12:1066–80.
90. Maret D, Sadr MS, Sadr ES, et al. Opposite roles of furin and PC5A in N-cadherin processing. Neoplasia 2012;14:880–92.
91. Balaram SK, Agrawal DK, Edwards JD. Insulin like growth factor-1 activates nuclear factor-kappaB and increases transcription of the intercellular adhesion molecule-1 gene in endothelial cells. Cardiovasc Surg 1999;7:91–7.
92. Ishizuka T, Takamizawa-Matsumoto M, Suzuki K, et al. Endothelin-1 enhances vascular cell adhesion molecule-1 expression in tumor necrosis factor alpha-stimulated vascular endothelial cells. Eur J Pharmacol 1999;369:237–45.
93. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. Embo J 1997;16:3898–911.
94. McColl BK, Paavonen K, Karnezis T, et al. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. Faseb J 2007;21:1088–98.
95. Siegfried G, Basak A, Cromlish JA, et al. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 2003;111:1723–32.
96. Xue Y, Lim S, Yang Y, et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med 2012;18:100–10.
97. Jechlinger M, Sommer A, Moriggl R, et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 2006;116:1561–70.
98. Weissmueller S, Manchado E, Saborowski M, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 2014;157:382–94.
99. Adams RH, Lohrum M, Klostermann A, et al. The chemorepulsive activity of secreted semaphorins is regulated by furin-dependent proteolytic processing. Embo J 1997;16:6077–86.
100. Christensen C, Ambartsumian N, Gilestro G, et al. Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. Cancer Res 2005;65:6167–77.
101. Varshavsky A, Kessler O, Abramovitch S, et al. Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases. Cancer Res 2008;68:6922–31.
102. Parker MW, Hellman LM, Xu P, et al. Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin. Biochemistry 2010;49:4068–75.
103. Casazza A, Kigel B, Maione F, et al. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. EMBO Mol Med 2012;4:234–50.
104. Couture F, Kwiatkowska A, Dory YL, et al. Therapeutic uses of furin and its inhibitors: a patent review. Expert Opin Ther Pat 2015;25:379–96.
105. Zhu J, Declercq J, Roucourt B, et al. Generation and characterization of non-competitive furin-inhibiting nanobodies. Biochem J 2012;448:73–82.
106. Dahms SO, Creemers JW, Schaub Y, et al. The structure of a furin-antibody complex explains non-competitive inhibition by steric exclusion of substrate conformers. Sci Rep 2016;6:34303.
107. Seidah NG, Mayer G, Zaid A, et al. The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol 2008;40:1111–25.
108. Senzer N, Barve M, Kuhn J, et al. Phase I trial of “bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancer. Molecular Ther 2012;20:679–86.
109. Nemunaitis J, Barve M, Orr D, et al. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG) in advanced cancer of the liver. Oncology 2014;87:21–9.
110. Ghisoli M, Barve M, Schneider R, et al. Pilot trial of FANG immunotherapy in Ewing's sarcoma. Mol Ther 2015;23:1103–9.
111. Ghisoli M, Barve M, Mennel R, et al. Three-year follow up of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (vigil) in metastatic advanced Ewing's sarcoma. Mol Ther 2016;24:1478–83.
112. Oh J, Barve M, Matthews CM, et al. Phase II study of Vigil(R) DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Gynecol Oncol 2016;143:504–10.
113. Hajdin K, D'Alessandro V, Niggli FK, et al. Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model. PLoS One 2010;5:e10445.
114. Weldon JE, Xiang L, Zhang J, et al. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther 2013:12:48–57.
115. Shan LQ, Ma S, Qiu XC, et al. A novel recombinant immuno-tBid with a furin site effectively suppresses the growth of HER2-positive osteosarcoma cells in vitro. Oncol Rep 2011;25:325–31.
116. Grosse SM, Tagalakis AD, Mustapa MF, et al. Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers. Faseb J 2010;24:2301–13.
117. Dragulescu-Andrasi A, Liang G, Rao J, In vivo bioluminescence imaging of furin activity in breast cancer cells using bioluminogenic substrates. Bioconjug Chem 2009;20:1660–6.
118. Dragulescu-Andrasi A, Kothapalli S-R, Tikhomirov Ga et al. Activatable oligomerizable imaging agents for photoacoustic imaging of furin-like activity in living subjects. J Am Chem Soc 2013;135:11015–22.
119. Cao CY, Shen YY, Wang JD, et al. Controlled intracellular self-assembly of gadolinium nanoparticles as smart molecular MR contrast agents. Sci Rep 2013;3:1024.
120. Yuan Y, Zhang J, Cao Q, et al. Intracellular disassembly of self-quenched nanoparticles turns NIR fluorescence on for sensing Furin activity in cells and in tumors. Anal Chem 2015;87:6180–5.
121. Huang YH, Lin KH, Liao CH, et al. Furin overexpression suppresses tumor growth and predicts a better postoperative disease-free survival in hepatocellular carcinoma. PLoS One 2012;7:e40738.
122. Declercq J, Brouwers B, Pruniau VP, et al. Liver-specific inactivation of the proprotein convertase Furin leads to increased hepatocellular carcinoma growth. Biomed Res Int 2015;2015:148651.
123. Gray KA, Yates B, Seal RL, et al. Genenames.org: the HGNC resources in 2015. Nucleic Acids Res 2015;43:D1079–85.
124. UniProt C. UniProt: a hub for protein information. Nucleic Acids Res 2015;43:D204–12.
125. Coordinators NR. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2016;44:D7–19.